Rheumatoid Arthritis Treatment - Small Molecules, Biologics, Therapy: Existing Biologics

Session Type: ACR Abstract Submissions
Monday, November 7, 2011: 2:30 PM-4:00 PM
W375c (McCormick Place West)
SessionSelect
Moderators: Joan M. Bathon, MD, Columbia University Medical Center and Peter M. Villiger, MD, Inselspital-University Hospital
Papers:
2:30 PM
Low Serum IgG Level After Rituximab Is Associated with An Increased Risk of Serious Infections in Rheumatoid Arthritis: Data of the AIR Registry
Jacques-Eric Gottenberg1, Philippe Ravaud2, Thomas Bardin3, Patrice Cacoub4, Alain G. Cantagrel5, Bernard G. Combe6, Maxime Dougados7, Rene-Marc Flipo8, Bertrand Godeau9, Loic Guillevin10, Xavier X. Le Loet11, Eric Hachulla12, Thierry Schaeverbeke13, Jean Sibilia14, Isabelle Pane15, Adelina Abbe15, Gabriel Baron16 and Xavier Mariette17, 1Strasbourg University Hospital, Strasbourg, France, 2Hotel Dieu University hospital, France, 3Service de Rhumatologie. Centre Viggo Petersen. Hôpital Lariboisiere, Paris, France, 4CHU Pitié-Salpêtrière, Paris, France, 5Hopital Purpan, Toulouse CEDEX 9, France, 6Hopital Lapeyronie, Montpellier, France, 7Paris-Descartes University, Cochin Hospital, Paris, France, 8Hopital R Salengro CHRU, Lille CEDEX, France, 9Service de médecine interne, Université Paris Est Créteil, AP-HP, Hôpital Mondor Créteil, France, Creteil, France, 10Cochin University Hospital, Paris, France, 11CHU de ROUEN, Rouen CEDEX, France, 12Internal Medicine, Lille CEDEX, France, 13Pellegrin Hospital, Bordeaux, France, 14Service de rhumatologie, Hôpitaux Universitaires de Strasbourg, Strasbourg, France, Strasbourg, France, 15France, 16Epidemiology, Paris, France, 17Université Paris-Sud, Le Kremlin Bicetre, France
2:45 PM
Risk Factors for Major Adverse Cardiovascular Events in Rheumatoid Arthritis Patients Treated with Tocilizumab
Vijay Rao1, Andrey Pavlov2, Micki Klearman1, David Musselman3, Jon T. Giles4, Joan M. Bathon4, Naveed Sattar5 and Janet S. Lee3, 1Genentech, San Francisco, CA, 2Everest, Toronto, 3Roche, Nutley, NJ, 4Columbia University Medical Center, New York, NY, 5University of Glasgow, Glasgow, United Kingdom
3:00 PM
B Cell Repopulation and Rheumatoid Factor Predict Duration of Response to Rituximab in Rheumatoid Arthritis
Edward M. Vital1, Sudipto Das2, Shouvik Dass1, Maya H. Buch3, Frederique Ponchel1, Andrew Rawstron1 and Paul Emery4, 1NIHR Leeds Biomedical Research Unit, University of Leeds and Leeds Teaching Hospitals NHS Trust, Leeds, United Kingdom, 2NIHR Leeds Musculoskeletal Biomedical Research Unit, University of Leeds and Leeds Teaching Hospitals NHS Trust, Leeds, United Kingdom, 3University of Leeds, Leeds, United Kingdom, 4Chapel Allerton Hospital, Leeds, United Kingdom
3:15 PM
Is Screening for JC-Polyomavirus by PCR or Detection of Antibodies Useful in Patients with Rheumatic Diseases Who Are Treated with Rituximab?
Jens Verheyen1, Eugen Feist2, Kseniya Maizus1, Zebulon Tolman1, Elena Knops1, Tim Waterboer3, Gerd R. Burmester4, Michael Pawlita3, Herbert Pfister1 and Andrea Rubbert1, 1University of Cologne, Cologne, Germany, 2Charité Medical School, Berlin, Germany, 3German Cancer Research Center, Heidelberg, Germany, 4Charité University Medicine, Berlin, Germany
3:30 PM
Efficacy of Different Doses of Rituximab for the Treatment of RA: Data From the CERERRA Collaboration
Katerina Chatzidionysiou1, Elisabeth Lie2, Evgeny L. Nasonov3, Galina Lukina3, Merete L. Hetland4, Ulrik Tarp5, Ioan Ancuta6, Karel Pavelka7, Dan C. Nordström8, Cem Gabay9, Helena Canhao10, Matija Tomsic11, Piet LC van Riel12, Juan J. Gomez-Reino13, Tore K. Kvien2 and Ronald F. van Vollenhoven1, 1Karolinska Institute, Stockholm, Sweden, 2Diakonhjemmet Hospital, Oslo, Norway, 3ARBITER, Institute of Rheumatology, Moscow, Russia, 4Copenhagen University Hospital at Glostrup, on behalf of DANBIO, Copenhagen, Denmark, 5Aarhus University Hospital, Aarhus, Denmark, 6Cantacuzino Hospital, Bucharest, Romania, 71Institute of Rheumatology, Department of Experimental Rheumatology, 1st Faculty of Medicine, Charles University in Prague, Prague, Czech Republic, 8ROB-FIN, Helsinki University Central Hospital, Helsinki, Finland, 9for the SCQM registry, University Hospitals of Geneva, Geneva, Switzerland, 10Lisbon Medical Academic Medical Center on behalf of Rheumatic Diseases Portuguese Register, Lisbon, Portugal, 11University Medical Centre Ljubjana, Ljubljana, Slovenia, 12Radboud University Nijmegen Medical Centre, Nijmegen, Netherlands, 13Hospital Clinico Universitario, Santiago, Spain
3:45 PM
Seropositivity and Response to RTX: Data From the CERERRA Collaboration
Katerina Chatzidionysiou1, Elisabeth Lie2, Evgeny L. Nasonov3, Galina Lukina3, Merete L. Hetland4, Ulrik Tarp5, Ioan Ancuta6, Karel Pavelka7, Dan C. Nordström8, Cem Gabay9, Helena Canhao10, Matija Tomsic11, Piet LCM Van Riel12, Juan J. Gomez-Reino13, Tore K. Kvien2 and Ronald F. van Vollenhoven1, 1Karolinska Institute, Stockholm, Sweden, 2Diakonhjemmet Hospital, Oslo, Norway, 3ARBITER, Institute of Rheumatology, Moscow, Russia, 4DANBIO, Copenhagen University Hospital at Glostrup, Copenhagen, Denmark, 5Aarhus University Hospital, Aarhus, Denmark, 6Cantacuzino Hospital, Bucharest, Romania, 71Institute of Rheumatology, Department of Experimental Rheumatology, 1st Faculty of Medicine, Charles University in Prague, Prague, Czech Republic, 8ROB-FIN, Helsinki University Central Hospital, Helsinki, Finland, 9for the SCQM registry, University Hospitals of Geneva, Geneva, Switzerland, 10Hosp Santa Maria, Lisbon, Portugal, 11University Medical Centre Ljubjana, Ljubljana, Slovenia, 12Radboud University Nijmegen Medical Centre, Nijmegen, Netherlands, 13Hospital Clinico Universitario, Santiago, Spain
See more of: ACR Abstract Submissions

To see other sessions for this day, use the date buttons to the left.